Risk-Adjusted Buy Rating on Wave Life Sciences: Differentiated Obesity Mechanism, Reset Valuation, and Long-Term Upside Despite 400 mg Uncertainty

Analyst Alec Stranahan of Bank of America Securities reiterated a Buy rating on Wave Life Sciences, reducing the price target to $21.00.

Alec Stranahan has given his Buy rating due to a combination of factors related to both the strengths and remaining optionality in Wave Life Sciences’ obesity program. Despite the sharp share price decline after the phase 1 update, he views the 240 mg cohort data as supportive of a differentiated, durable mechanism, with deepening visceral fat reduction over six months, preservation of lean mass, sustained Activin E suppression that could enable infrequent dosing, and an acceptable safety profile.

At the same time, he acknowledges that the 400 mg cohort underperformed expectations and did not deliver a clear dose-response or a convincing path yet to the 5% weight-loss benchmark as monotherapy. However, he still sees meaningful upside in higher-BMI patients and in combination or maintenance settings alongside incretin therapies, and reflects the increased uncertainty by lowering peak monotherapy penetration and probability of success while maintaining a positive stance. This risk-adjusted view, combined with the reset valuation after the selloff and a still-attractive long-term opportunity, underpins his continued Buy rating and $21 price objective.

Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Novavax, and Day One Biopharmaceuticals. According to TipRanks, Stranahan has an average return of 5.0% and a 49.85% success rate on recommended stocks.

In another report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $35.00 price target.